[Use of potassium canrenoate in cardiosurgery].
The influence of canrenoate of potassium, a new injectable antialdosteronic, on serum, urinary and intraerythrocyte ionograms has been evaluated as part of a random controlled study on patients submitted to ECC heart surgery. The results show that the drug maintains correct ionic homoestasis and gradualises and potentiates diuresis, in association with furosemide. The possible clinical implications of these results are discussed.
D000328:Adult; D000368:Aged; D002191:Canrenoic Acid / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D005112:Extracorporeal Circulation; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007008:Hypokalemia / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011183:Postoperative Complications; D011245:Pregnadienes / Q000627:therapeutic use*; D014883:Water-Electrolyte Imbalance / Q000209:etiology
D011245:Pregnadienes; D005665:Furosemide; D002191:Canrenoic Acid
Impiego del canrenoato di potassio in cardiochirurgia.